Numbers and cytotoxicities of CD3⁺CD56⁺ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia

References

• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480 - 9; http://dx.doi.org/10.1038/nature10673; PMID: 22193102
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringdén O, Rozman C, Speck B, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555 - 62; PMID: 2297567
   PubMed Web of Science ®Google Scholar
• Görgün G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005; 115:1797 - 805; http://dx.doi.org/10.1172/JCI24176; PMID: 15965501
   PubMed Web of Science ®Google Scholar
• Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F, Quackenbush J, Croce CM, Gribben JG. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A 2009; 106:6250 - 5; http://dx.doi.org/10.1073/pnas.0901166106; PMID: 19332800
   PubMed Web of Science ®Google Scholar
• Dustin ML, Cooper JA. The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling. Nat Immunol 2000; 1:23 - 9; http://dx.doi.org/10.1038/76877; PMID: 10881170
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118:2427 - 37; PMID: 18551193
   PubMed Web of Science ®Google Scholar
• Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21:573 - 83; http://dx.doi.org/10.1016/S0167-5699(00)01735-7; PMID: 11094262
   PubMedGoogle Scholar
• Joyce S. CD1d and natural T cells: how their properties jump-start the immune system. Cell Mol Life Sci 2001; 58:442 - 69; http://dx.doi.org/10.1007/PL00000869; PMID: 11315191
   PubMed Web of Science ®Google Scholar
• Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 2000; 164:1148 - 52; PMID: 10640724
   PubMed Web of Science ®Google Scholar
• Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, Ami K, Hiraide H, Sekine I. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 2001; 103:281 - 90; http://dx.doi.org/10.1046/j.1365-2567.2001.01248.x; PMID: 11454057
   PubMed Web of Science ®Google Scholar
• Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994; 153:1687 - 96; PMID: 7519209
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG. Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 1997; 74:51 - 6; http://dx.doi.org/10.1007/s002770050257; PMID: 9063373
   PubMed Web of Science ®Google Scholar
• Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998; 92:3318 - 27; PMID: 9787169
   PubMed Web of Science ®Google Scholar
• Gritzapis AD, Dimitroulopoulos D, Paraskevas E, Baxevanis CN, Papamichail M. Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol Immunother 2002; 51:440 - 8; PMID: 12202905
   PubMed Web of Science ®Google Scholar
• Guven H, Gilljam M, Chambers BJ, Ljunggren HG, Christensson B, Kimby E, Dilber MS. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia 2003; 17:1973 - 80; http://dx.doi.org/10.1038/sj.leu.2403083; PMID: 14513047
   PubMed Web of Science ®Google Scholar
• Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, Lee AM, Lister TA, Gribben JG. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 2009; 114:3909 - 16; http://dx.doi.org/10.1182/blood-2009-02-206946; PMID: 19710498
   PubMed Web of Science ®Google Scholar
• Okada H, Nagamura-Inoue T, Mori Y, Takahashi TA. Expansion of Valpha24(+)Vbeta11(+) NKT cells from cord blood mononuclear cells using IL-15, IL-7 and Flt3-L depends on monocytes. Eur J Immunol 2006; 36:236 - 44; http://dx.doi.org/10.1002/eji.200526085; PMID: 16380959
   PubMed Web of Science ®Google Scholar
• Chamoto K, Takeshima T, Kosaka A, Tsuji T, Matsuzaki J, Togashi Y, Ikeda H, Nishimura T. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo. Immunol Lett 2004; 95:5 - 11; http://dx.doi.org/10.1016/j.imlet.2004.04.012; PMID: 15325792
   PubMed Web of Science ®Google Scholar
• Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004; 199:947 - 57; http://dx.doi.org/10.1084/jem.20031389; PMID: 15051763
   PubMed Web of Science ®Google Scholar
• Seino K, Taniguchi M. Functionally distinct NKT cell subsets and subtypes. J Exp Med 2005; 202:1623 - 6; http://dx.doi.org/10.1084/jem.20051600; PMID: 16365145
   PubMed Web of Science ®Google Scholar
• Gütgemann S, Frank S, Strehl J, Schmidt-Wolf IG. Cytokine-induced killer cells are type II natural killer T cells. Ger Med Sci 2007; 5:Doc07; PMID: 19675715
   PubMedGoogle Scholar
• Rumi C, Rutella S, Teofili L, Etuk B, Ortu La Barbera E, Micciulli G, Voso MT, Leone G. RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpression. Exp Hematol 1997; 25:246 - 51; PMID: 9091301
   PubMed Web of Science ®Google Scholar